The ISBGroup Blog

The ISBGroup Blog

About the blog

Here you can read about everything that's happening in the ISB Group.

AstraZeneca Award

NewsPosted by Elin Nyman Thu, February 08, 2018 12:19:19

Elin was recently awarded the prestigious AstraZeneca Science Award 2017 in the category Post-Doc. All the short-listed candidates was invited to the ceremoni with dinner at the Guildhall in the centre of the historic city of Cambridge. The top-right picture shows Elin being interviewed directly after the prize ceremony answering the typical question "how does it feel".

New publication in the Journal of Biological Chemistry

NewsPosted by Elin Nyman Thu, May 26, 2016 09:41:23
Signaling to regulate FOXO1 may be the most important mechanism for insulin to control transcription. In spite of this, little is known about how insulin regulates FOXO1 and how FOXO1 may contribute to insulin resistance in adipocytes, which is the most critical cell type in the development of insulin resistance. We report a detailed mechanistic analysis of insulin control of FOXO1 in human adipocytes obtained from non-diabetic subjects and from patients with T2D.

Systems-wide experimental and modeling analysis of insulin signaling through FOXO1 in human adipocytes, normally and in type 2 diabetes.



Abstract selected for oral presentation: SBMC 2016

EventsPosted by Elin Nyman Wed, March 23, 2016 13:51:31


We have had an abstract selected for an oral presentation at the 6th Conference on Systems Biology of Mammalian Cells in Munich. The abstract is about our long-term work with diabetes modeling. Gunnar will hold the presentation April 8th in the session Systems Medicine & Systems Pharmacology chaired by Werner Mewes & Frank Lammert. We hope to see you there!



New publication: review on systems pharmacology of diabetes

NewsPosted by Elin Nyman Wed, March 23, 2016 13:48:00

We have published an opinion paper in Interface Focus:


Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes


In the paper, we present an analysis of the current situation where mathematical modeling steadily becomes more and more appreciated as a tool in biomedical research and in drug development projects. However, there are still major issues to overcome before modeling can become one of the mainstream tools in such projects, and even more so before modeling can be used directly in the actual treatment of patients. We review current state-of-the-art models in diabetes research and address the most important issues to overcome before such models can be used in drug development and in the clinic.

We involved authors from AstraZeneca, Uppsala University, and Eindhoven Technical University with competences reaching from disease progression modeling, to mixed-effect PKPD modeling in the field of diabetes to get a broad take on the subject. The paper is part of a theme issue The Human Physiome: a necessary key to the creative destruction of medicine organized by Stig W. Omholt and Peter Hunter from the Virtual Physiological Human institute.